Search Results - "Laub, P"

Refine Results
  1. 1

    No time for drifting: Comparing performance and applicability of signal detrending algorithms for real-time fMRI by Kopel, R., Sladky, R., Laub, P., Koush, Y., Robineau, F., Hutton, C., Weiskopf, N., Vuilleumier, P., Van De Ville, D., Scharnowski, F.

    Published in NeuroImage (Orlando, Fla.) (01-05-2019)
    “…As a consequence of recent technological advances in the field of functional magnetic resonance imaging (fMRI), results can now be made available in real-time…”
    Get full text
    Journal Article
  2. 2

    Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells by Roberts, D, Schick, J, Conway, S, Biade, S, Laub, P B, Stevenson, J P, Hamilton, T C, O'Dwyer, P J, Johnson, S W

    Published in British journal of cancer (28-03-2005)
    “…Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding the molecular basis for…”
    Get full text
    Journal Article
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8

    Microscopic Benign and Invasive Malignant Neoplasms and a Cancer-Prone Phenotype in Prophylactic Oophorectomies by Salazar, Hernando, Godwin, Andrew K., Daly, Mary B., Laub, Paul B., Hogan, W. Michael, Rosenblum, Norman, Boente, Matthew P., Lynch, Henry T., Hamilton, Thomas C.

    “…Background The occurrence of approximately 5% of common epithelial malignant tumors of the ovary can be traced to inheritance of risk. One prohylactic strategy…”
    Get full text
    Journal Article
  9. 9

    Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines by JOHNSON, S. W, LAUB, P. B, BEESLEY, J. S, OZOLS, R. F, HAMILTON, T. C

    Published in Cancer research (Chicago, Ill.) (01-03-1997)
    “…We have examined a panel of 12 unrelated human ovarian cancer cell lines derived from patients who were either untreated or treated with platinum-based…”
    Get full text
    Journal Article
  10. 10

    Population Pharmacokinetic Model for Topotecan Derived From Phase I Clinical Trials by GALLO, J. M, LAUB, P. B, ROWINSKY, E. K, GROCHOW, L. B, BAKER, S. D

    Published in Journal of clinical oncology (01-06-2000)
    “…To characterize the pharmacokinetics of topotecan in a population model that would identify patient variables or covariates that appreciably impacted on its…”
    Get full text
    Journal Article
  11. 11

    NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data by Laub, P B, Gallo, J M

    Published in Journal of pharmaceutical sciences (01-04-1996)
    “…The computer program NCOMP performs noncompartmental analysis of pharmacokinetic data obtained from iv bolus, continuous infusion, and oral modes of…”
    Get more information
    Journal Article
  12. 12

    Structure-Based Optimization of Peptide Inhibitors of Mammalian Ribonucleotide Reductase by Pellegrini, Maria, Liehr, Sebastian, Fisher, Alison L, Laub, Paul B, Cooperman, Barry S, Mierke, Dale F

    Published in Biochemistry (Easton) (10-10-2000)
    “…Mammalian ribonucleotide reductase (mRR), a potential target for cancer intervention, is composed of two subunits, mR1 and mR2, whose association is critical…”
    Get full text
    Journal Article
  13. 13

    A noncovalent peptide complex as a model for an early folding intermediate of cytochrome c by Wu, L C, Laub, P B, Elöve, G A, Carey, J, Roder, H

    Published in Biochemistry (Easton) (28-09-1993)
    “…Horse heart cytochrome c is one of a small number of proteins for which the folding pathway has been elucidated in structural detail by pulsed hydrogen…”
    Get full text
    Journal Article
  14. 14

    Localized solution structure refinement of an F45W variant of ubiquitin using stochastic boundary molecular dynamics and NMR distance restraints by Laub, Paul B., Khorasanizadeh, Sepideh, Roder, Heinrich

    Published in Protein science (01-05-1995)
    “…The local structure within an 8‐Å radius around residue 45 of a recombinant F45W variant of human ubiquitin has been determined using 67 interproton distance…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion by O'DWYER, P. J, LAUB, P. B, GALLO, J. M, DEMARIA, D, QIAN, M, REILLY, D, GIANTONIO, B, JOHNSTON, A. L, WU, E. Y, BAUMAN, L, CLENDENINN, N. J

    Published in Clinical cancer research (01-10-1996)
    “…AG331 (N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2, 6-diaminobenz-[c,d]-indole glucuronate) is a lipophilic thymidylate synthase inhibitor with activity in…”
    Get full text
    Journal Article
  18. 18

    NMR structure of an inhibitory R2 C-terminal peptide bound to mouse ribonucleotide reductase R1 subunit by Fisher, Alison, Laub, Paul B, Cooperman, Barry S

    Published in Nature structural biology (01-11-1995)
    “…The structure of peptide N-AcYTLDADF when bound to the large subunit of mouse ribonucleotide reductase has been elucidated by transfer NOE. This structure…”
    Get full text
    Journal Article
  19. 19

    Some Aspects of the Aggregation Problem in the Dividend-Earnings Relationship by Laub, P. Michael

    “…Four models of the relationship between dividends and earnings are estimated to study the effects of different types of aggregation. The data indicate that the…”
    Get full text
    Journal Article
  20. 20